Amgen Inc. (NASDAQ: AMGN) is a leading biotechnology company, Headquartered in Thousand Oaks, California, Amgen focuses on developing innovative therapies for serious illnesses. The company specializes in areas such as oncology, cardiovascular disease, and osteoporosis. With a global presence, Amgen is known for blockbuster drugs like Enbrel and Neulasta.
Key Takeaways:
- Amgen’s stock price is projected to grow steadily over the next three decades
- Compound Annual Growth Rate (CAGR) indicates strong long-term potential
- Factors such as pipeline developments, market trends, and economic conditions will play crucial roles in price fluctuations
- Long-term investors may find Amgen an attractive option for portfolio growth
Overview of Amgen Inc.
Amgen, short for Applied Molecular Genetics, was founded in 1980 in Thousand Oaks, California. Since its inception, the company has been dedicated to developing innovative human therapeutics. Amgen’s breakthrough was with EPOGEN®, a treatment for anemia associated with chronic kidney disease. The success of EPOGEN® helped Amgen become a leading biotechnology company.
The company’s focus areas include oncology, cardiovascular disease, inflammation, bone health, and neuroscience. With a strong emphasis on research and development, Amgen continues to drive innovation in the biotechnology sector.
key points of Amgen’s significant acquisitions:
- Immunex Corporation (2002):
- Acquired for $4.50/share plus 0.44 Amgen shares
- Added important drugs like EPOGEN, NEUPOGEN, and ENBREL
- Abgenix (2006):
- $2.2 billion cash acquisition
- Provided full ownership of panitumumab and eliminated denosumab royalty
- Horizon Therapeutics plc (2022):
- $27.8 billion acquisition at $116.50/share
- Added TEPEZZA, KRYSTEXXA, and UPLIZNA to inflammation portfolio
These acquisitions significantly expanded Amgen’s drug portfolio and market position.
Amgen Inc. Company Profile
| Country | United States of America |
| Ticker Symbol | AMGN |
| Exchange | NASDAQ |
| Founded | 1980 |
| IPO Date | 1983 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26,700 |
| CEO | Robert A. Bradway |
| Market Cap (July 8, 2024) | $168.34 billion |
| Website | amgen |
Amgen Inc. (AMGN) Balance Sheet Analysis
Amgen Inc. (NASDAQ: AMGN) released its 2023 year-end balance sheet, revealing substantial growth. Total assets surged to $97.2 billion from $65.1 billion in 2022, while total liabilities increased to $90.9 billion.
The company’s financial position showed mixed results. Total equity stood at $6.2 billion, with total capitalization reaching $69.4 billion. Amgen maintained a positive working capital of $11.9 billion. However, net tangible assets were negative at -$45.0 billion, indicating significant intangible assets and goodwill on the balance sheet.
Debt levels rose considerably, with total debt at $64.6 billion and net debt at $53.7 billion. This increase likely reflects recent acquisitions, particularly the major purchase of Horizon Therapeutics in 2022.
The company’s share count remained relatively stable at 535.4 million shares issued. Overall, Amgen’s 2023 balance sheet demonstrates the company’s continued expansion and strategic investments, albeit with increased leverage.
Balance Sheet Data Source: finance.yahoo
Amgen Inc. Stock Price History
Amgen Inc. (NASDAQ: AMGN) had its IPO in the year 1983. Amgen (AMGN) has executed five stock splits since its inception. These occurred in 1990, 1991, 1995, and twice in 1999. The most recent split was on November 22, 1999. Each split was 2:1, except for a 3:1 split in 1991. Collectively, these splits have resulted in one pre-1990 share equaling 48 shares today, significantly increasing share accessibility.1
As of July 5, 2024, Amgen’s stock price stands at $310.88.
Amgen Stock Price Forecast 2024
In 2024, we anticipate Amgen’s stock to continue its upward trend. The company’s robust pipeline and strategic initiatives are expected to drive growth. Our analysis suggests the following price range for 2024:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2024 | $260.00 | $320.00 | $340.00 |
In 2024, Amgen is expected to focus on expanding its biosimilar portfolio and advancing its oncology pipeline. The company’s efforts in developing innovative therapies for cardiovascular diseases and osteoporosis may also contribute to investor confidence.
We project a potential growth of 2.93% from the current price of $310.88 to an average price of $320.00 by the end of 2024. This modest increase reflects market expectations and the company’s steady performance.
Amgen Stock Price Forecast 2025
Moving into 2025, Amgen is poised to capitalize on its research investments and potential new drug approvals. Our forecast for 2025 is as follows:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $325.00 | $350.00 | $375.00 |
By 2025, Amgen’s investments in next-generation bispecific T-cell engager (BiTE) immunotherapies are anticipated to yield results. The company’s expansion into the Asia-Pacific market, particularly China, could drive growth. Advancements in Amgen’s inflammation and nephrology portfolios may also contribute to stock price appreciation.
The average price of $350.00 represents a 9.38% increase from 2024’s average. This growth is attributed to anticipated market expansion and the maturation of key products in Amgen’s portfolio.
Amgen Stock Price Forecast 2026
In 2026, we expect Amgen to continue its growth trajectory. Our projections for this year are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $360.00 | $390.00 | $420.00 |
In 2026, Amgen’s long-term investments in genetics and genomics research are expected to start bearing fruit. The company’s focus on precision medicine and personalized healthcare solutions could differentiate it in the market. Potential breakthroughs in Amgen’s neuroscience program, particularly in Alzheimer’s and Parkinson’s diseases, may significantly impact investor sentiment. The maturation of Amgen’s biosimilar portfolio could also contribute to revenue growth and stock price appreciation.
The average price of $390.00 signifies an 11.43% increase from 2025. This substantial growth is based on the expected success of Amgen’s pipeline products and potential market share gains.
Amgen Stock Price Forecast 2027
As we look towards 2027, Amgen’s strategic initiatives are expected to bear fruit. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $400.00 | $435.00 | $470.00 |
By 2027, Amgen’s strategic partnerships and collaborations in artificial intelligence and machine learning for drug discovery are anticipated to enhance its R&D productivity. The company’s efforts in sustainable manufacturing practices may appeal to environmentally conscious investors. Amgen’s potential expansion into gene therapy and RNA therapeutics could open new growth avenues.
The projected average price of $435.00 represents an 11.54% increase from 2026. This growth reflects the anticipated positive impact of Amgen’s long-term research and development efforts.
Amgen Stock Price Forecast 2028
In 2028, we expect Amgen to maintain its growth momentum. Our projections for this year are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $450.00 | $490.00 | $530.00 |
In 2028, Amgen’s investments in digital health solutions and patient engagement platforms are expected to improve treatment outcomes and boost market share. The company’s focus on developing therapies for rare diseases could yield high-value products. Amgen’s efforts in improving drug delivery systems and extending product lifecycles may contribute to sustained growth.
The average price of $490.00 indicates a 12.64% increase from 2027. This growth is based on expected market expansion and the potential success of Amgen’s innovative therapies.
Amgen Stock Price Forecast 2029
As we approach the end of the decade, Amgen’s stock is projected to continue its upward trend. Our forecast for 2029 is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $510.00 | $555.00 | $600.00 |
By 2029, Amgen’s long-term investments in cell therapy and regenerative medicine are anticipated to yield innovative treatments. The company’s expansion into emerging markets and potential strategic acquisitions could drive growth. Amgen’s focus on developing therapies for age-related diseases may position it well in aging populations.
The average price of $555.00 represents a 13.27% increase from 2028. This growth reflects the anticipated market reception of Amgen’s expanding product portfolio.
Amgen Stock Price Forecast 2030
Entering the new decade, Amgen is expected to maintain its position as a leader in the biotechnology sector. Our projections for 2030 are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $580.00 | $630.00 | $680.00 |
In 2030, Amgen’s efforts in developing novel biologics and next-generation protein engineering technologies are expected to strengthen its product pipeline. The company’s investments in sustainable practices and corporate social responsibility may enhance its brand value. Potential breakthroughs in Amgen’s cardiovascular disease therapies could significantly impact market perception.
The average price of $630.00 signifies a 13.51% increase from 2029. This substantial growth is based on the expected maturation of Amgen’s pipeline products and potential market expansions.
Related: Danaher Corporation (DHR) Stock Forecast & Price Prediction
Amgen Stock Price Forecast 2031
In 2031, we anticipate Amgen to continue its growth trajectory. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $660.00 | $715.00 | $770.00 |
By 2031, Amgen’s long-term investments in nanotechnology and targeted drug delivery systems are anticipated to yield innovative therapies. The company’s focus on developing treatments for emerging global health threats could open new markets. Amgen’s potential expansion into digital therapeutics and health tech solutions may diversify its revenue streams.
The projected average price of $715.00 represents a 13.49% increase from 2030. This growth reflects the anticipated success of Amgen’s long-term strategic initiatives.
Amgen Stock Price Forecast 2032
Moving into 2032, Amgen’s stock is expected to maintain its upward momentum. Our projections for this year are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $750.00 | $810.00 | $870.00 |
In 2032, Amgen’s strategic investments in biotechnology startups and incubators are expected to fuel innovation and growth. The company’s efforts in developing personalized nutrition and wellness solutions may expand its market reach. Potential breakthroughs in Amgen’s immunology program could significantly impact investor sentiment.
The average price of $810.00 indicates a 13.29% increase from 2031. This growth is based on expected market developments and the potential success of Amgen’s innovative therapies.
Amgen Stock Price Forecast 2033
In 2033, we expect Amgen to continue its strong performance. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $850.00 | $920.00 | $990.00 |
By 2033, Amgen’s long-term research in epigenetics and gene regulation is anticipated to yield novel therapeutic approaches. The company’s focus on developing treatments for mental health disorders could open new growth avenues. Amgen’s potential expansion into bioelectronic medicine may diversify its product portfolio.
The average price of $920.00 represents a 13.58% increase from 2032. This growth reflects the anticipated positive impact of Amgen’s research and development efforts.
Amgen Stock Price Forecast 2034
As we look towards 2034, Amgen’s stock is projected to maintain its growth trend. Our projections for this year are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $960.00 | $1,040.00 | $1,120.00 |
In 2034, Amgen’s investments in quantum computing for drug discovery are expected to accelerate its R&D processes. The company’s efforts in developing therapies for space medicine could position it uniquely in the market. Potential breakthroughs in Amgen’s anti-aging research may significantly impact market perception.
The average price of $1,040.00 signifies a 13.04% increase from 2033. This growth is based on expected market expansion and the potential success of Amgen’s product pipeline.
Amgen Stock Price Forecast 2035
In 2035, we anticipate Amgen to continue its upward trajectory. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $1,080.00 | $1,170.00 | $1,260.00 |
By 2035, Amgen’s long-term investments in synthetic biology and bioengineering are anticipated to yield innovative biomanufacturing solutions. The company’s focus on developing treatments for climate change-related health issues could open new markets. Amgen’s potential expansion into personalized microbiome therapies may diversify its product offerings.
The projected average price of $1,170.00 represents a 12.50% increase from 2034. This growth reflects the anticipated market reception of Amgen’s expanding product portfolio.
Amgen Stock Price Forecast 2036
Moving into 2036, Amgen’s stock is expected to maintain its strong performance. Our projections for this year are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $1,220.00 | $1,320.00 | $1,420.00 |
In 2036, Amgen’s strategic investments in brain-computer interfaces for neurological disorders are expected to position it at the forefront of neuroscience. The company’s efforts in developing advanced bioinformatics tools may enhance its R&D capabilities. Potential breakthroughs in Amgen’s research on reversing cellular aging could significantly impact investor sentiment.
The average price of $1,320.00 indicates a 12.82% increase from 2035. This growth is based on expected market developments and the potential success of Amgen’s innovative therapies.
Amgen Stock Price Forecast 2037
In 2037, we expect Amgen to continue its growth momentum. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $1,380.00 | $1,490.00 | $1,600.00 |
By 2037, Amgen’s long-term research in xenotransplantation and organ regeneration is anticipated to address critical healthcare challenges. The company’s focus on developing treatments for extraterrestrial environments could open unique growth opportunities. Amgen’s potential expansion into AI-driven predictive healthcare may revolutionize disease prevention.
The average price of $1,490.00 represents a 12.88% increase from 2036. This growth reflects the anticipated positive impact of Amgen’s long-term strategic initiatives.
Amgen Stock Price Forecast 2038
As we approach the end of the 2030s, Amgen’s stock is projected to maintain its upward trend. Our projections for 2038 are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $1,560.00 | $1,680.00 | $1,800.00 |
In 2038, Amgen’s investments in quantum biology for drug discovery are expected to yield novel therapeutic approaches. The company’s efforts in developing solutions for human enhancement and augmentation could position it in emerging markets. Potential breakthroughs in Amgen’s research on cellular reprogramming may significantly impact market perception.
The average price of $1,680.00 signifies a 12.75% increase from 2037. This growth is based on expected market expansion and the potential success of Amgen’s product pipeline.
Amgen Stock Price Forecast 2039
In 2039, we anticipate Amgen to continue its strong performance. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $1,760.00 | $1,890.00 | $2,020.00 |
By 2039, Amgen’s long-term investments in biocomputing and DNA data storage are anticipated to revolutionize its R&D processes. The company’s focus on developing treatments for digital-age health issues could open new growth avenues. Amgen’s potential expansion into biomechanical interfaces for prosthetics may diversify its product portfolio.
The projected average price of $1,890.00 represents a 12.50% increase from 2038. This growth reflects the anticipated market reception of Amgen’s expanding product portfolio.
Amgen Stock Price Forecast 2040
Entering the 2040s, Amgen’s stock is expected to maintain its growth trajectory. Our projections for 2040 are:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $1,980.00 | $2,130.00 | $2,280.00 |
In 2040, Amgen’s strategic investments in molecular nanotechnology for precision medicine are expected to yield groundbreaking therapies. The company’s efforts in developing treatments for cognitive enhancement may position it uniquely in the market. Potential breakthroughs in Amgen’s research on reversing neurodegenerative diseases could significantly impact investor sentiment.
The average price of $2,130.00 indicates a 12.70% increase from 2039. This growth is based on expected market developments and the potential success of Amgen’s innovative therapies.
Amgen Stock Price Forecast 2050
Looking ahead to 2050, we project significant growth for Amgen’s stock. Our forecast for this year is:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $6,700.00 | $7,200.00 | $7,700.00 |
By 2050, Amgen is anticipated to be at the forefront of integrating biotechnology with artificial intelligence, potentially revolutionizing personalized medicine. The company’s long-term investments in longevity research and age-reversal therapies could position it as a leader in addressing global aging populations. Amgen’s focus on developing solutions for potential interplanetary health challenges may open unprecedented growth opportunities.
The projected average price of $7,200.00 represents a substantial increase from previous years. This long-term projection is based on the anticipated success of Amgen’s research and development efforts, potential market expansions, and the company’s ability to adapt to future healthcare trends.
Conclusion
Our analysis of Amgen Inc. (NASDAQ: AMGN) stock price forecasts from 2024 to 2050 reveals a consistent upward trend. We project the stock to reach an average price of $7,200.00 by 2050. This represents a remarkable growth over nearly three decades.
The Compound Annual Growth Rate (CAGR) for this period is approximately 11.63%, indicating strong long-term potential for investors.
FAQs
1. What is the future of AMGN share price?
The future of Amgen’s (AMGN) share price appears to be positive with steady growth projected over the coming decades. Starting from $310.88 in July 2024, the stock is forecasted to reach an average price of $7,200.00 by 2050, with a Compound Annual Growth Rate (CAGR) of approximately 11.63%.
2. What is the AMGN share prediction for 2030?
According to the forecast in the article, the average share price for Amgen in 2030 is projected to be $630.00, with a low of $580.00 and a high of $680.00.
3. What is the AMGN 10 year outlook?
The 10-year outlook for Amgen, from 2024 to 2034, shows consistent growth. By 2034, the average share price is projected to reach $1,040.00, representing significant growth from the 2024 price of $320.00.
4. Is AMGN a buy, hold, or sell?
Amgen (AMGN) could be considered a cautious buy or hold for long-term investors. The projections show steady growth over the next few decades, with a compound annual growth rate (CAGR) of 11.63% from 2024 to 2050. This suggests strong long-term potential.
5. Who are the major competitors of AMGN?
The major competitors of AMGN (Amgen Inc.) in the biopharmaceutical industry include:
- Pfizer (PFE)
- Novartis (NVS)
- Roche (RHHBY)
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
- Merck & Co. (MRK)
- Sanofi (SNY)
- Gilead Sciences (GILD)
- Bristol-Myers Squibb (BMY)
- Regeneron Pharmaceuticals (REGN)
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
Source:
